Molecular susceptibility weighted imaging of the glioma rim in a mouse model

Journal of Neuroscience Methods

Volumn 226, Issue , 2014, Pages 132-138

  Blasiak, Barbara ^a,b   Landry, James ^a   Tyson, Randy ^c   Sharp, Jonathan ^c   Iqbal, Umar ^f   Abulrob, Abedelnasser ^e,f   Rushforth, David ^a   Matyas, John ^a   Ponjevic, Dragana ^a   Sutherland, Garnette R ^a   Wolfsberger, Stefan ^d   Tomanek, Boguslaw ^a,b,g  

^a UNIVERSITY OF CALGARY   (Canada)

^b INSTITUTE OF NUCLEAR PHYSICS   (Poland)

^c Alberta Innovates Technology Futures   (Canada)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF OTTAWA   (Canada)

^f NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^g Thunder Bay Regional Research Institute   (Canada)

Author keywords

Glioma; Molecular MRI; SWI; Targeted contrast agents

Indexed keywords

CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE;

ANIMAL; BRAIN; BRAIN NEOPLASMS; CANCER TRANSPLANTATION; COMPARATIVE STUDY; DIAGNOSTIC USE; DISEASE MODEL; GLIOMA; HISTOCHEMISTRY; MALE; MOUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUDE MOUSE; PATHOLOGY; PROCEDURES; TIME; TUMOR CELL LINE;

ANIMALS; BRAIN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FERRIC COMPOUNDS; GLIOMA; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MALE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PRUSSIAN BLUE REACTION; TIME FACTORS;

EID: 84894450918     PISSN: 01650270     EISSN: 1872678X     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2014.01.034     Document Type: Article

References (42)

1. Aghi M., Gaviani P., Henson J.W., Batchelor T.T., Louis D.N., Barker F.G. Magnetic resonance imaging characteristics predicts epidermal growth factor receptor amplification status in glioblastomas. Clin Cancer Res 2005, 12(9):8600-8605.
2. 2 changes in an early mouse brain tumor. Magn Reson Imaging 2010, 28:784-789.
3. Cai W., Chen X. Multimodality molecular imaging of tumor angiogensis. J Nucl Med 2008, 49:113-128.
4. Colman H., Zhang L., Sulman E.P., McDonald J.M., Shooshani N.L., Rivera A., et al. A multigene factor predictor of outcome in glioblastoma. Neuro-oncol 2009, 12(1):49-57.
5. Corot C., Robert P., Idee J.M., Port M. Recent advances in iron oxide nanocrystal technology for medical imaging. Adv Drug Deliv Rev 2006, 58(14):1471-1504.
6. Ellegala D.B., Leong-Poi H., Carpenter J.E., Klibanov A.L., Kaul S., Shaffrey M.E., et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to αvß3. Circulation 2003, 94:336-341.
7. Gambarota G., van Laarhoven H.W.M., Philippens M., Lok J., van der Kogel A., Punt C.J.A., et al. Assessment of absolute blood volume in carcinoma by USPIO contrast-enhanced MRI. Magn Reson Imaging 2006, 24(3):279-289.
8. Gambarota G., Leenders W., Maass C., Wesseling P., van der Kogel B., van Tellingen O., et al. Characterisation of tumor vasculature in mouse brain by USPIO contrast-enhanced MRI. Br J Cancer 2008, 98:1784-1789.
9. Grabner G., Nobauer I., Elandt K., Kronnerwetter C., Trattinig S., Preusser M. Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7T. Magn Reson Imaging 2012, 30:139-147.
10. Haacke M.E., Xu Y., Cheng X.C., Reichenbach J.R. Sucseptibility-weighted imaging (SWI). Magn Reson Med 2004, 52(3):612-618.
11. Haacke M.E., Mittal S., Wu Z., Neelavalli J., Cheng Y.C.N. Susceptibility-weighted imaging: technical aspects and clinical applications. Am J Neuroradiol 2009, 30:19-30.
12. Haimes A.B., Zimmerman R.D., Morgello S., Weingarten K., Becker R.D., Jennis R., et al. MR imaging of brain absesses. Am J Roentgenol 1989, 152(5):1073-1085.
13. Hamzah J., Altin J.G., Herringson T., Parish C.R., Hämmerling G.J., O'Donoghue H., et al. Targeted liposomal delivery of TLR9 ligands activates spontaneous antitumor immunity in an autochthonous cancer model. J Immunol 2009, 183(2):1091-1098.
14. Huber D.L. Synthesis, properties and applications of iron nanoparticles. Small 2005, 1(5):482-501.
15. Iqbal U., Albaghdadi H., Luo Y., Arbabi M., Desvaux C., Veres T., et al. Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies. Br J Cancer 2010, 103(10):1606-1616.
16. Jiang W., Xiang C., Cazacu S., Broadie C., Mikkelson T. Insulin-like growth factor binding protein 7 mediates glioma cell growth and migration. Neoplasia 2008, 10(12):1335-1342.
17. Kelly J., Daumas-Duport C., Kispert D.B., Kall B.A., Scheithauer B.W. Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 1987, 66:865-874.
18. LaConte L.E., Nitin N., Zurkiya O., Caruntu D., O'Connor C.J., Hu X., et al. Coating thickness of magnetic iron oxide nanoparticles affects R2 relaxivity. J Magn Reson Imaging 2007, 26:1634-1641.
19. Lawaczeck R., Memzel M., Pietsch H. Superparamagnetic iron oxide particles: contrast media for magnetic resonance imaging. Appl Organomet Chem 2004, 18(10):506-516.
20. Lee B.C., Vo K.D., Kido D.K., Mukherjee P., Reichenbach J., Lin W., et al. MR high-resolution blood oxygenation level dependent venography of occult (low-field) vascular lesions. Am J Neuroradiol 1999, 20:1239-1242.
21. Lupo J., Banerjee S., Hammond K.E., Kelley D.A.C., Xu D., Chang S.M., et al. GRAPPA-based susceptibility-weighted imaging of normal volunteers and patients with brain tumours at 7T. Magn Reson Imaging 2009, 27(4):480-488.
22. Moenninghoff C., Maderwald S., Theysohn J.M., Kraff O., Ladd M.E., Hindy N.E., et al. Imaging of adult astrocytic brain tumor with 7T MRI: preliminary results. Eur Radiol 2010, 20:704-713.
23. 2 relaxation times in characterizing contrast enhancing brain tumors and regions of peritumoral edema. J Magn Reson Imaging 2005, 21(6):701-708.
24. Ohagak H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglialgliomas. J Neuropathol Exp Neurol 2005, 64:479-489.
25. Pinker K., Noebauer-Huhmann I.M., Stavrou I., Hoeftberger R., Szomolanyi P., Weber M., et al. High-field, high-resolution, susceptibility-weighted magnetic resonance imaging: improved image quality by addition of contrast agent and higher field strength in patients with brain tumors. Neuroradiology 2008, 50:9-16.
26. Rauscher A., Sedlacik J., Barth M., Haacke E.M., Reichenbach J.R. Noninvasive assessment of vascular architecture and function during modulated blood oxygenation using susceptibility weighted magnetic resonance imaging. Magn Reson Med 2005, 54:87-95.
27. Rock K., Mcardle O., Forde P., Dunne M., Fitzpatrick D., O'Neill B., et al. A clinical review of treatment outcomes in glioblastoma multiforme-the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival?. Br J Radiol 2012, 85(1017):729-733.
28. Runge V.M., Clanton J.A., Partian C.L., James A.E. Respiratory gating in magnetic resonance imaging at 0.5 Tesla. Radiology 1984, 151:521-523.
29. Santra S., Zhang P., Wang K., Tan W. Conjugation of biomolecules with luminophore-doped silica nanoparticles for photostable biomarkers. Anal Chem 2005, 22(9):4988-4993.
30. 2 hypointensity associated with ring-enhancing brain lesions can help to differenciate pathology. Diagn Neuroradiol 2006, 48:143-149.
31. Seghal V., Delproposto Z., Haddar Z., Tong K.A., Wycliffe N., Kido D.K., et al. Susceptibility-weighted imaging to visualize blood products and improve tumor contrast in the study of brain masses. J Magn Reson Imaging 2010, 22(4):41-51.
32. Suwa T., Ozawa S., Ueda M., Ando N., Kitajima M. Magnetic resonance imaging of esophageal squamous cell carcinoma using magnetite particles coeated with aniti-epidermal growth factor receptor antibody. Int J Cancer 1998, 75(4):626-634.
33. Swanson K.R., Bridge C., Murray J.D., Alvord E.C. Virtual and real brain tumors: using mathematical modeling to quantify glioma growth and invasion. J Neurol Sci 2003, 216(1):1-10.
34. Tan I.J., van Schijndel R.A., Pouwels P.J., van Walderveen M.A., Reichenbach J.R., Manoliu R.A., et al. MR venography of multiple sclerosis. Am J Neuroradiol 2000, 21:1039-1042.
35. Tomanek B., Iqbal U., Blasiak B., Abulrob A., Albaghdadi H., Matyas J.R., et al. Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging. Neuro-oncol 2012, 14(1):53-63.
36. Tong K.A., Ashwal S., Obenause A., Nickerson J.P., Kido D., Haake E.M., et al. imaging:a review of clinical applications in children. Am J Neuroradiol 2008, 29:36-50.
37. Vajkoczy P., Menger M.D., Vollmar B., Schilling L., Schmiedek P., Hirth K.P., et al. Inhibition of tumor growth, angiogenesis, and microcirculation by the novel Flk-1 inhibitor SU5416 as assessed by intravital multi-fluorescence videomicroscopy. Neoplasia 1999, 1:31-41.
38. Villalba A.M., Okuducu A.F., Deimling A. The evolution of our understanding on glioma. Brain Pathol 2008, 18:455-463.
39. Wang S., Zhou J. Diffusion tensor magnetic resonance imaging of rat glioma models: a correlation study of MR imaging and histology. J Comput Assist Tomogr 2012, 36(6):739-744.
40. Wang Y.X., Hussain S.M., Krestin G.P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol 2001, 11(11):2319-2331.
41. Weinstein J., Varallyay C.G., Dosa E., Gahramanov S., Hamilton B., Rooney W.D., et al. Superparamagnetic iron oxide nanoparticles: diagnostic magnetic resonance imaging and potential therapeutic applications in neurooncology and central nervous. J Cereb Blood Metab 2010, 30:15-35.
42. Yetkin A.B., Haughton V.M. A typical demyelinating lesions in patients with MS. Neuroradiology 1995, 37:284-286.